BIII-890-CL. Boehringer Ingelheim.
BIII-890-CL is a non-orally active sodium channel blocker under development by Boehringer Ingelheim Corp for the potential treatment of thromboembolic stroke. By April 2001, the compound was in phase II clinical trials for this indication, with trials ongoing in June 2002. The compound is also under investigation for its potential use in the treatment of pain.
Meythaler
Jay
J
University of Alabama at Birmingham, School of Medicine, Dept of Physical Medicine and Rehabilitation, 157 Spain Rehabilitation Center, 619 19th St South, Birmingham, AL 35249-7330, USA. JMeythal@uab.edu
D000818:Animals; D001575:Benzomorphans / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000379:methods*; D006801:Humans; D010146:Pain / Q000188:drug therapy; D026941:Sodium Channel Blockers / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use
C408069:BIII 890 CL; D001575:Benzomorphans; D026941:Sodium Channel Blockers